INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Inovio Pharmaceuticals
National Cancer Institute (NCI)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Novartis
Dana-Farber Cancer Institute
St. Joseph's Hospital and Medical Center, Phoenix
NRG Oncology
Debiopharm International SA
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Jonsson Comprehensive Cancer Center
Grupo Español de Investigación en Neurooncología
Mayo Clinic
M.D. Anderson Cancer Center
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sun Yat-sen University
Northwestern University
Baptist Health South Florida
AstraZeneca
University of Iowa
University of Iowa
European Organisation for Research and Treatment of Cancer - EORTC
Washington University School of Medicine
St. Joseph's Hospital and Medical Center, Phoenix
Stanford University
National Cancer Institute (NCI)
Washington University School of Medicine
M.D. Anderson Cancer Center
NeuGATE Theranostics
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
M.D. Anderson Cancer Center
Tactical Therapeutics, Inc.
Mayo Clinic
University of Iowa
Medical College of Wisconsin
Emory University
European Organisation for Research and Treatment of Cancer - EORTC
Northwestern University
University of Pittsburgh
BioMimetix JV, LLC
M.D. Anderson Cancer Center
Thomas Jefferson University
Mayo Clinic
St. Joseph's Hospital and Medical Center, Phoenix
Centre Georges Francois Leclerc
Centre Jean Perrin
National Cancer Institute (NCI)